Core Points - The company is holding its first extraordinary general meeting of shareholders in 2025 to ensure the rights of all shareholders and maintain order during the meeting [1] - The meeting will include both on-site and online voting, with specific time frames for participation [5] - The agenda includes proposals to cancel the supervisory board and amend the company's articles of association, as well as to revise and establish related governance systems [6][9] Group 1: Meeting Procedures - Only shareholders, their representatives, company directors, supervisors, senior management, and invited personnel are allowed to attend the meeting [1] - Shareholders must register 30 minutes before the meeting and present identification documents to verify their eligibility [2] - The meeting will follow a structured agenda, and shareholders have the right to speak, inquire, and vote [2][3] Group 2: Voting and Decision-Making - Voting will be conducted through a combination of on-site and online methods, with results announced after the meeting [2][4] - Shareholders must express their opinions on the proposals by indicating agreement, disagreement, or abstention on the voting ballot [4] - The company will appoint representatives to oversee the counting and verification of votes [4][7] Group 3: Proposals and Governance - The first proposal involves the cancellation of the supervisory board and amendments to the articles of association, with the supervisory board's powers being transferred to the audit committee of the board [6][9] - The second proposal includes the revision and establishment of governance systems to enhance the company's operational standards and protect shareholder rights [9]

浙江东方基因生物制品股份有限公司 2025 年第一次临时股东大会 证券简称：东方生物 证券代码：688298 浙江东方基因生物制品股份有限公司 2025 年第一次临时股东大会会议资料 2025 年 9 月 15 日 1 浙江东方基因生物制品股份有限公司 2025 年第一次临时股东大会 浙江东方基因生物制品股份有限公司 2025 年第一次临时股东大会会议须知 为维护浙江东方基因生物制品股份有限公司（以下简称"公司"）全体股东 的合法权益，确保股东大会的正常秩序和议事效率，保证股东大会如期、顺利召 开，根据《中华人民共和国公司法》《中华人民共和国证券法》《浙江东方基因 生物制品股份有限公司章程》《浙江东方基因生物制品股份有限公司股东大会议 事规则》等相关规定，特制定本股东大会会议须知。 一、为保证本次股东大会的严肃性和正常秩序，切实维护与会股东（或股东 代表）的合法权益，除出席会议的股东（或股东代表）、公司董事、监事、高级 管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他人员进入会 场。 二、出席会议的股东（或股东代表）须在会议召开前 30 分钟到会议现场办 理签到手续，并按股东大会通知的相关要求，出 ...

Group 1 - The fentanyl concept sector increased by 0.65%, ranking first among concept sectors, with two stocks rising, including Renfu Pharmaceutical which hit the daily limit [1] - The main funds net inflow into the fentanyl concept sector was 577 million yuan, with Renfu Pharmaceutical receiving the largest net inflow of 571 million yuan [2][3] - The net inflow ratios for leading stocks in the fentanyl concept were 18.07% for Renfu Pharmaceutical, 8.67% for Enhua Pharmaceutical, and 2.06% for Lingrui Pharmaceutical [3] Group 2 - The stocks with the largest declines in the fentanyl concept sector included Dongfang Biology, Wanfu Biology, and Botuo Biology, with declines of 1.88%, 1.54%, and 1.36% respectively [1][2] - The trading volume and turnover rates for the leading stocks in the fentanyl concept were notable, with Renfu Pharmaceutical showing a turnover rate of 9.23% [3]

Core Viewpoint - The company, Dongfang Biological, announced a share buyback plan, indicating a strategic move to enhance shareholder value and confidence in the company's future performance [1] Summary by Categories - **Share Buyback Details** - The company repurchased a total of 982,262 shares, which represents 0.4872% of its total share capital [1]

Group 1 - The company, Oriental Bio, announced a share buyback program, having repurchased approximately 982,300 shares, which accounts for 0.4872% of its total share capital of about 202 million shares [1] - The buyback was conducted through the Shanghai Stock Exchange with a total expenditure of approximately 27.89 million RMB, with the lowest and highest purchase prices being 27.5 RMB and 29.52 RMB per share, respectively [1] - As of the report, Oriental Bio's market capitalization stands at 5.6 billion RMB [1] Group 2 - For the fiscal year 2024, the company's revenue composition indicates that the in vitro diagnostics sector contributes 97.99% to total revenue, while other business segments account for 2.01% [1]

Core Viewpoint - Dongfang Biological (688298.SH) has repurchased a total of 982,262 shares, representing 0.4872% of the company's total share capital, as of August 31, 2025 [1] Summary by Category Share Repurchase - The company has conducted share repurchases through the Shanghai Stock Exchange system via centralized bidding [1] - The minimum repurchase price was 27.50 CNY per share, while the maximum price reached 29.52 CNY per share [1] - The total amount paid for the repurchased shares was approximately 27.888 million CNY [1]

证券代码：688298 证券简称：东方生物 公告编号：2025-047 浙江东方基因生物制品股份有限公司 关于以集中竞价交易方式回购公司股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特此公告。 一、回购股份的基本情况 浙江东方基因生物制品股份有限公司（以下简称"公司"）于 2025 年 6 月 26 日召开第三届董事会第十三次会议，审议通过了《关于以集中竞价交易方式回购 公司股份的方案》，同意公司以自有资金或自筹资金（含股票回购专项贷款资金等） 通过上海证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币 普通股（A 股）股票，本次回购的股份将用于维护公司价值及股东权益，回购价格 不超过人民币 32.44 元/股（含），回购资金总额不低于人民币 2,500 ...

Core Points - The board of directors of Zhejiang Oriental Gene Biological Products Co., Ltd. held its 14th meeting of the third board on August 28, 2025, to review and vote on various proposals [1][2][3] - All proposals received unanimous approval with 6 votes in favor, 0 against, and 0 abstentions [2][3][4] - The independent directors and audit committee have reviewed and approved the financial information in the semi-annual report [1][2] Summary by Sections - **Board Meeting Details** - The meeting was conducted via email and communication, with all 6 directors present [1] - The meeting complied with legal regulations and company bylaws [1] - **Voting Results** - All proposals were passed with effective votes of 6 in favor, indicating strong consensus among the board members [2][3][4] - Specific proposals include the semi-annual fundraising report and amendments to the company’s governance structure [2][3] - **Future Actions** - Certain proposals will require further approval from the shareholders' meeting [2][5] - The company plans to implement revised governance systems following the necessary approvals [5][6]

Core Points - The Supervisory Board of Zhejiang Oriental Gene Biological Products Co., Ltd. confirmed that the procedures for preparing and reviewing the 2025 semi-annual report comply with legal and regulatory requirements, and the report accurately reflects the company's actual situation without any false records or significant omissions [1][2] - The Supervisory Board has decided to abolish the Supervisory Board and its functions will be transferred to the Audit Committee of the Board of Directors, with relevant internal regulations being revised accordingly [2][3] - The proposal to cancel the Supervisory Board requires approval from the shareholders' meeting before implementation [2]

Meeting Information - The shareholder meeting is scheduled for September 15, 2025, at 10:00 AM [1] - The meeting will be held at the conference room of Zhejiang Orient Gene Biotech Co., Ltd. in Anji County, Huzhou City, Zhejiang Province [1] - Voting will be conducted through both on-site and online methods using the Shanghai Stock Exchange's network voting system [1] Voting Procedures - The network voting will be available from 9:15 AM to 3:00 PM on the day of the meeting [1] - Shareholders can vote via the trading system or the internet voting platform [4] - Duplicate votes through different methods will be counted based on the first vote cast [4] Shareholder Eligibility - Shareholders registered by the close of trading on September 8, 2025, are eligible to attend the meeting [5] - Shareholders can appoint proxies to attend and vote on their behalf [5] Registration Process - Registration for the meeting can be done on-site or through mail, fax, or email for distant shareholders [6] - Specific documentation is required for different types of shareholders, including personal identification and proof of shareholding [6] Other Meeting Details - The meeting is expected to last half a day, and attendees are responsible for their own travel and accommodation expenses [6] - Attendees should arrive at least 30 minutes early for registration [6]